1. Sung, H, Ferlay, J, Siegel, RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209–249.
Google Scholar | Crossref | Medline2. Bredin, P, Walshe, J, Denduluri, N. Systemic therapy for metastatic HER2-positive breast cancer. Semin Oncol 2020; 47: 259–269.
Google Scholar | Crossref | Medline3. Chan, W-L, Lam, TC, Lam, KO, et al. Local and systemic treatment for HER2-positive breast cancer with brain metastases: a comprehensive review. Ther Adv Med Oncol 2020; 12: 1758835920953729.
Google Scholar | SAGE Journals4. DeSantis, CE, Ma, J, Gaudet, MM, et al. Breast cancer statistics, 2019. CA Cancer J Clin 2019; 69: 438–451.
Google Scholar | Crossref | Medline5. Köhler, G, Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495–497.
Google Scholar | Crossref | Medline | ISI6. Hudziak, RM, Lewis, GD, Winget, M, et al. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 1989; 9: 1165–1172.
Google Scholar | Crossref | Medline | ISI7. Slamon, DJ, Leyland-Jones, B, Shak, S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783–792.
Google Scholar | Crossref | Medline | ISI8. Chien, AJ, Rugo, HS. Tyrosine kinase inhibitors for human epidermal growth factor receptor 2-positive metastatic breast cancer: is personalizing therapy within reach? J Clin Oncol 2017; 35: 3089–3091.
Google Scholar | Crossref | Medline9. Spector, N, Xia, W, El-Hariry, I, et al. HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors. Breast Cancer Res 2007; 9: 205.
Google Scholar | Crossref10. Cameron, D, Casey, M, Oliva, C, et al. Lapatinib plus capecitabine in women with HER-2–positive advanced breast cancer: final survival analysis of a phase III randomized trial. Oncologist 2010; 15: 924–934.
Google Scholar | Crossref | Medline | ISI11. Geyer, CE, Forster, J, Lindquist, D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355: 2733–2743.
Google Scholar | Crossref | Medline | ISI12. Verma, S, Miles, D, Gianni, L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012; 367: 1783–1791.
Google Scholar | Crossref | Medline | ISI13. Barroso-Sousa, R, Tolaney, SM. Clinical development of new antibody–drug conjugates in breast cancer: to infinity and beyond. Biodrugs 2021; 35: 159–174.
Google Scholar | Crossref | Medline14. Christensen, SC, Krogh, BO, Jensen, A, et al. Characterization of basigin monoclonal antibodies for receptor-mediated drug delivery to the brain. Sci Rep 2020; 10: 14582.
Google Scholar | Crossref | Medline15. Devanaboyina, M, Bailey, MM, Hamouda, DM. A retrospective study of characteristics and survival in patients with breast cancer brain metastases classified by subtype using NCI SEER registry. J Clin Oncol 2021; 39: 1031.
Google Scholar | Crossref16. Aversa, C, Rossi, V, Geuna, E, et al. Metastatic breast cancer subtypes and central nervous system metastases. Breast 2014; 23: 623–628.
Google Scholar | Crossref | Medline | ISI17. Kim, JS, Kim, IA. Evolving treatment strategies of brain metastases from breast cancer: current status and future direction. Ther Adv Med Oncol 2020; 12: 1758835920936117.
Google Scholar | SAGE Journals18. Venur, VA, Leone, JP. Targeted therapies for brain metastases from breast cancer. Int J Mol Sci 2016; 17: 1543.
Google Scholar | Crossref19. Swain, SM, Kim, S-B, Cortés, J, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2013; 14: 461–471.
Google Scholar | Crossref | Medline | ISI20. Cardoso, F, Paluch-Shimon, S, Senkus, E, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol 2020; 31: 1623–1649.
Google Scholar | Crossref | Medline21. Giordano, SH, Temin, S, Chandarlapaty, S, et al. Systemic therapy for patients with advanced human epidermal growth factor receptor 2–positive breast cancer: ASCO clinical practice guideline update. J Clin Oncol 2018; 36: 2736–2740.
Google Scholar | Crossref | Medline22. Cortés, J, Kim, S, Chung, W, et al. LBA1 Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): results of the randomized phase III DESTINY-Breast03 study. Ann Oncol 2021; 32: S1287–S1288.
Google Scholar | Crossref23. Cameron, D, Casey, M, Press, M, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008; 112: 533–543.
Google Scholar | Crossref | Medline | ISI24. von Minckwitz, G, du Bois, A, Schmidt, M, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German breast group 26/breast international group 03-05 study. J Clin Oncol 2009; 27: 1999–2006.
Google Scholar | Crossref | Medline | ISI25. Modi, S, Saura, C, Yamashita, T, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med 2020; 382: 610–621.
Google Scholar | Crossref | Medline26. Rugo, HS, Im, S-A, Cardoso, F, et al. Efficacy of margetuximab vs trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer: a phase 3 randomized clinical trial. JAMA Oncol 2021; 7: 573–584.
Google Scholar | Crossref | Medline27. Bang, Y-J, Giaccone, G, Im, S, et al. First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors. Ann Oncol 2017; 28: 855–861.
Google Scholar | Crossref | Medline28. Mezni, E, Vicier, C, Guerin, M, et al. New therapeutics in HER2-positive advanced breast cancer: towards a change in clinical practices? Cancers 2020; 12: 1573.
Google Scholar | Crossref29. Pernas, S, Tolaney, SM. HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance. Ther Adv Med Oncol 2019; 11: 1758835919833519.
Google Scholar | SAGE Journals30. Hamilton, EP, Petit, T, Pistilli, B, et al. Clinical activity of MCLA-128 (zenocutuzumab), trastuzumab, and vinorelbine in HER2 amplified metastatic breast cancer (MBC) patients (pts) who had progressed on anti-HER2 ADCs. J Clin Oncol 2020; 38: 3093.
Google Scholar | Crossref31. Saura, C, Oliveira, M, Feng, Y-H, et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ⩾2 HER2-directed regimens: phase III NALA trial. J Clin Oncol 2020; 38: 3138.
Google Scholar | Crossref | Medline32. Murthy, RK, Loi, S, Okines, A, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med 2020; 382: 597–609.
Google Scholar | Crossref | Medline33. Brufsky, A, Zulfiqar, M, Peguero, J, et al. A phase 2 study of poziotinib in patients with HER2-positive metastatic breast cancer heavily pre-treated with HER2-targeted therapy. Philadelphia, PA: American Association Cancer Research, 2021.
Google Scholar | Crossref34. Tesch, ME, Gelmon, KA. Targeting HER2 in breast cancer: latest developments on treatment sequencing and the introduction of biosimilars. Drugs 2020; 80: 1811.
Google Scholar | Crossref | Medline35. Krop, IE, Kim, S-B, González-Martín, A, et al. Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15: 689–699.
Google Scholar | Crossref | Medline | ISI36. Krop, IE, Kim, S-B, Martin, AG, et al. Trastuzumab emtansine versus treatment of physician’s choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol 2017; 18: 743–754.
Google Scholar | Crossref | Medline37. Yamamoto, Y, Iwata, H, Naruto, T, et al. Abstract PD3-11: a randomized, open-label, phase III trial of pertuzumab re-treatment in HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab, and chemotherapy: the Japan Breast Cancer Research Group-M05 (PRECIOUS) study, 2021, https://cancerres.aacrjournals.org/content/81/4_Supplement/PD3-11.short
Google Scholar38. Curigliano, G, Mueller, V, Borges, VF, et al. Updated results of tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB). Philadelphia, PA: Wolters Kluwer Health, 2021.
Google Scholar | Crossref39. Manich, C, Modi, S, Krop, I, et al. 279P trastuzumab deruxtecan (T-DXd) in patients with HER2-positive metastatic breast cancer (MBC): updated survival results from a phase II trial (DESTINY-Breast01). Ann Oncol 2021; 32: S485–S486.
Google Scholar40. Modi, S, Saura, C, Yamashita, T, et al. Updated results from DESTINY-breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd) in HER2 positive metastatic breast cancer. In: San Antonio Breast Cancer Symposium®, 8–11 December 2020, https://www.physiciansweekly.com/wp-content/uploads/2021/01/Modi_PD3-06_DESTINY-Breast01.pdf
Google Scholar | Crossref41. CancerNetwork.com . FDA approves T-DM1 (Kadcyla) for HER2-positive breast cancer, https://www.cancernetwork.com/view/fda-approves-t-dm1-kadcyla-her2-positive-breast-cancer (accessed 18 May 2021).
Google Scholar42. Gradishar, WJ, Anderson, BO, Abraham, J, et al. Breast cancer, version 3.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2020; 18: 452–478.
Google Scholar | Crossref | Medline43. Freedman, RA, Gelman, RS, Anders, CK, et al. TBCRC 022: a phase II trial of neratinib and capecitabine for patients with human epidermal growth factor receptor 2–positive breast cancer and brain metastases. J Clin Oncol 2019; 37: 1081.
Google Scholar | Crossref | Medline44. Awada, A, Colomer, R, Inoue, K, et al. Neratinib plus paclitaxel vs trastuzumab plus paclitaxel in previously untreated metastatic ERBB2-positive breast cancer: the NEfERT-T randomized clinical trial. JAMA Oncol 2016; 2: 1557–1564.
Google Scholar | Crossref | Medline45. Globenewswire.com . MacroGenics announces final overall survival results from SOPHIA study of MARGENZA™ in patients with HER2-positive metastatic breast cancer, https://www.globenewswire.com/news-release/2021/09/07/2292944/0/en/MacroGenics-Announces-Final-Overall-Survival-Results-from-SOPHIA-Study-of-MARGENZA-in-Patients-with-HER2-Positive-Metastatic-Breast-Cancer.html (accessed 7 October 2021).
Google Scholar46. Manich, C, O’Shaughnessy, J, Aftimos, P, et al. LBA15 Primary outcome of the phase III SYD985. 002/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician’s choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer. Ann Oncol 2021; 32: S1288.
Google Scholar | Crossref47. Stringer-Reasor, EM, O’Brien, BJ, Topletz-Erickson, A, et al. Pharmacokinetic (PK) analyses in CSF and plasma from TBCRC049, an ongoing trial to assess the safety and efficacy of the combination of tucatinib, trastuzumab and capecitabine for the treatment of leptomeningeal metastasis (LM) in HER2 positive breast cancer. Philadelphia, PA: Wolters Kluwer Health, 2021.
Google Scholar48. Lin, NU, Borges, V, Anders, C, et al. Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial, 2020, https://air.unimi.it/handle/2434/824756#.YatA5dBByUk
Google Scholar | Crossref49. Jerusalem, GHM, Park, YH, Yamashita, T, et al. Trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer with brain metastases: a subgroup analysis of the DESTINY-Breast01 trial. J Clin Oncol 2021; 39: 526–526.
Google Scholar |